Table. Institutional Dataa.
| Variable | No. | Source/comment |
|---|---|---|
| Age, median (range), y | 62 (16-92) | NA |
| Sex | ||
| Male | 405 | NA |
| Female | 383 | |
| Tumor size | ||
| Small | 105 | Classified as small (stage 1), medium (stage 2), large (stage 3 or 4) as defined by the American Joint Committee on Cancer, 7th edition11 |
| Medium | 210 | |
| Large | 161 | |
| Prognostic method | ||
| FISH | 148 | Singh et al, 20167 |
| GEP | 215 | Brinkley et al, 20208 |
| Whole-exome sequencing and SS | 312 | Yavuzyigitoglu et al, 201610 |
| NGS | 113 | Thornton et al, 20209 |
| Prognosis group | ||
| Good prognosis | 237 | Tumors having disomy chromosome 3 (FISH), class 1 (GEP), absence of BAP1 or SF3B1 gene mutation (SS, NGS) |
| Bad prognosis | 353 | Tumors having monosomy chromosome 3 (FISH), Class 2 (GEP), presence of BAP1 or SF3B1 gene mutation (SS, NGS) |
| Mutation status | ||
| BAP1 mutant | 204 | In only those tested (n = 355) |
| SF3B1 mutant | 60 | |
| Wild type | 91 | |
| Systemic status | ||
| Alive | ||
| With metastasis | 11 | NA |
| Without metastasis | 506 | NA |
| Dead | ||
| With metastasis | 162 | NA |
| Without metastasis | 109 | NA |
Abbreviations: FISH, fluorescent in situ hybridization; GEP, gene expression profiling; NA, not applicable; NGS, next-generation sequencing; SS, Sanger sequencing.
a
Pooled data sets of molecularly prognosticated patients. Sources and profile (n = 788). Tumor samples were analyzed by FISH, GEP, or, to detect mutations, whole-exome sequencing validated by SS or targeted NGS.